Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fitting new modalities into practice guidelines

R L Theriault1

  • 1Nellie B. Connelly Breast Center, University of Texas M. D. Anderson Cancer Center, Houston, USA.

Oncology (Williston Park, N.Y.)
|January 16, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers.

Breast cancer research and treatment·2011
Same author

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.

British journal of cancer·2010
Same author

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

British journal of cancer·2010
Same author

Effects of chronic hepatitis C infection on the treatment of breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding.

Endocrine-related cancer·2005

Pamidronate (Aredia) is now standard care for breast cancer osteolytic metastases at M. D. Anderson. Achieving this involved clinical trials and addressing practical and ethical issues in cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Practice Guidelines

Background:

  • Osteolytic metastases from breast cancer pose significant treatment challenges.
  • The bisphosphonate pamidronate (Aredia) has emerged as a key agent in managing these bone metastases.
  • Establishing a new treatment as standard of care requires rigorous evaluation.

Purpose of the Study:

  • To describe the process by which pamidronate (Aredia) became part of the standard of care for osteolytic metastases in breast cancer patients at M. D. Anderson.
  • To explore the criteria and decision-making involved in defining standard of care for oncologic therapies.

Main Methods:

  • Review of clinical trial data and adoption pathways for pamidronate.
  • Analysis of the practical and ethical considerations in implementing new cancer treatments.

Related Experiment Videos

  • Examination of the definition and determination of standard of care in oncology.

    • Main Results:

    • Pamidronate (Aredia) has been integrated into the standard care pathway at M. D. Anderson for treating osteolytic metastases.
    • The process highlights the complex journey from drug approval to routine clinical use.
    • Key questions regarding standard of care criteria and decision-making were addressed.

    Conclusions:

    • The integration of pamidronate exemplifies the rigorous process required to establish new standards in cancer care.
    • Understanding the pathway to standard of care is crucial for future treatment adoptions.
    • This case study provides insights into the evolution of oncologic treatment protocols.